FDA Approves Cancer Biomarker Test, CMS Suggests Insurance Coverage Options

Last week, the FDA approved the FoundationOne CDx (F1CDx), a next-generation sequencing (NGS)-based in vitro diagnostic (IVD) test that can discover mutations in 324 genes and 2 genomic signatures in solid tumors, according to a press release.
In support of the groundbreaking approval, the Centers for Medicare & Medicaid Services (CMS) issued a national coverage suggestion for the F1CDx.
The F1CDx is the second IVD to be approved and reviewed by the FDA and CMS under the Parallel Review Program, according to the release. This program increases Medicare access to novel technologies.
Under the FDA-CMS program, the agencies both review medical devices to speed the time to FDA approval and Medicare’s coverage of the device. The program is open to new technologies and devices that fall within the scope of Part A or Part B, according to the release.
“By leveraging 2 policy efforts aimed at expediting access to promising new technologies, we’ve been able to bring patients faster access to a breakthrough diagnostic that can help doctors tailor cancer treatments to improve medical outcomes and potentially reduce health care costs,” said FDA Commissioner Scott Gottlieb, MD. “The FDA’s Breakthrough Device Program and Parallel Review with CMS allowed the sponsor to win approval for this novel diagnostic and secure an immediate proposed Medicare coverage determination within 6 months of the FDA receiving the product application.”
The CMS said that the F1CDx provides more information about various genetic mutations that can help improve the management of patients with cancer compared with other approved tests.  
F1CDx sequences a patient’s tumor sample to detect mutations, alterations, and molecular changes, according to the release. Clinical testing suggests the test may be accurate nearly 95% of the time.
Based on the results, the novel test may be able to match patients with approved targeted therapies for patients with non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, or ovarian cancer, according to the CMS.
Additionally, since the test searches through hundreds of mutations, duplicative biopsies can be avoided, according to the release.
“The F1CDx can help cancer patients and their health care professionals make more informed care decisions without the often invasive process of extracting tumor samples multiple times to determine eligibility for a single treatment or enrollment in a clinical trial,” said Jeffrey Shuren, MD, director of the FDA Center for Devices and Radiological Health. “With the run of one test, patients and health care professionals can now evaluate several appropriate disease management options.”
The CMS also proposed national coverage of the test for Medicare patients with advanced cancer who have not previously received NGS testing. The proposed plan provides coverage for NGS IVD tests to help patients and physicians make informed treatment decisions and can also increase enrollment in clinical trials, according to the release.
“Through parallel review and collaboration, we speed access to innovative diagnostics, so that doctors are better able to deliver the best quality care to their patients and patients have access to these state-of-the-art tests,” said Seema Verma, administrator of CMS. “Our proposal establishes clear expectations, while at the same time delivering better outcomes for the people we serve.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.